Friday, March 31, 2023 7:09:01 PM
I certainly acknowledge that Revive has to own a bit of the process. But it is clear that the FDA gets to play king maker. They can control the tempo of the trial, move the target just enough so that the little guys struggle to change course, add a little more to what is required in testing, etc...
Throughout Revive's course we would receive the occasional update that the FDA was going to hand hold them to and through the next phase. But the timelines that we would be given was something crazy like 3-4 months at a time. When that time would lapse, the landscape would have changed just enough that we could see relevancy slipping.
We may never know all of what was truly behind it. Very likely some dropped balls on Revive's part. But in the meantime, the big's were basically being fast tracked left and right, only months or years later to learn that corners were cut in testing, or in some cases data was falsified (bad or damning data was intentionally left out), and they floated through unchecked.
Maybe there is hope yet. But I think most of us now understand that the FDA doesn't truly have the publics best interest at hand.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM